Combination Therapy: Histone Deacetylase Inhibitors and Platinum-based Chemotherapeutics for Cancer

Overview

Journal Cancer Lett

Specialty Oncology

Date 2012 Oct 4

PMID 23032720

Citations 39

Authors

Himashinie V K Diyabalanage

Michael L Granda

Jacob M Hooker

Affiliations

Soon will be listed here.

Abstract

One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has been proven in vitro and in vivo in recent studies for many cancer types and stages. In this review, we discuss the most commonly used combinations of histone deacetylase inhibitors and platinum based drugs in the context of their possible mechanisms, efficiency, efficacy, and related drawbacks in preclinical and clinical studies.

Citing Articles

Targeting the epigenome with advanced delivery strategies for epigenetic modulators.

Guha S, Jagadeesan Y, Pandey M, Mittal A, Chitkara D Bioeng Transl Med. 2025; 10(1):e10710.

PMID: 39801754 PMC: 11711227. DOI: 10.1002/btm2.10710.

Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma.

Demir S, Hotes A, Schmid T, Cairo S, Indersie E, Pisano C J Exp Clin Cancer Res. 2024; 43(1):299.

PMID: 39529166 PMC: 11556140. DOI: 10.1186/s13046-024-03221-6.

Graph domain adaptation-based framework for gene expression enhancement and cell type identification in large-scale spatially resolved transcriptomics.

Shen R, Cheng M, Wang W, Fan Q, Yan H, Wen J Brief Bioinform. 2024; 25(6).

PMID: 39508445 PMC: 11541786. DOI: 10.1093/bib/bbae576.

Advances in targeting histone deacetylase for treatment of solid tumors.

Shi M, Xu Y, Fu X, Pan D, Lu X, Xiao Y J Hematol Oncol. 2024; 17(1):37.

PMID: 38822399 PMC: 11143662. DOI: 10.1186/s13045-024-01551-8.

Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer.

Mani Giri P, Kumar A, Salu P, Sathish V, Reindl K, Mallik S Biomed Pharmacother. 2024; 175:116743.

PMID: 38759290 PMC: 11268367. DOI: 10.1016/j.biopha.2024.116743.

References

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A . Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res. 2009; 15(8):2818-28. DOI: 10.1158/1078-0432.CCR-08-1579. View

Devane C . Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003; 37 Suppl 2:25-42. View

Kim M, Kwon H, Lee Y, Baek J, Jang J, Lee S . Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7(4):437-43. DOI: 10.1038/86507. View

Marks P, Xu W . Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4):600-8. PMC: 2766855. DOI: 10.1002/jcb.22185. View

Rodenhiser D, Mann M . Epigenetics and human disease: translating basic biology into clinical applications. CMAJ. 2006; 174(3):341-8. PMC: 1373719. DOI: 10.1503/cmaj.050774. View

Garcia-Manero G, Issa J . Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 2005; 23(7):635-42. DOI: 10.1080/07357900500283119. View

Nelson S, Ferguson L, Denny W . DNA and the chromosome - varied targets for chemotherapy. Cell Chromosome. 2004; 3(1):2. PMC: 421739. DOI: 10.1186/1475-9268-3-2. View

McLaughlin F, La Thangue N . Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol. 2004; 68(6):1139-44. DOI: 10.1016/j.bcp.2004.05.034. View

Griffith D, Duff B, Suponitsky K, Kavanagh K, Morgan M, Egan D . Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity. J Inorg Biochem. 2011; 105(6):793-9. DOI: 10.1016/j.jinorgbio.2011.03.001. View

10.

Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M . Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci. 2008; 99(2):376-84. PMC: 11158297. DOI: 10.1111/j.1349-7006.2007.00669.x. View

11.

Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M . Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005; 11(17):6382-9. DOI: 10.1158/1078-0432.CCR-05-0344. View

12.

Choi J, Kwon H, Yoon B, Kim J, Han S, Joo H . Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001; 92(12):1300-4. PMC: 5926683. DOI: 10.1111/j.1349-7006.2001.tb02153.x. View

13.

Li E . Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet. 2002; 3(9):662-73. DOI: 10.1038/nrg887. View

14.

Grayson D, Kundakovic M, Sharma R . Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?. Mol Pharmacol. 2009; 77(2):126-35. DOI: 10.1124/mol.109.061333. View

15.

Carew J, Giles F, Nawrocki S . Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008; 269(1):7-17. DOI: 10.1016/j.canlet.2008.03.037. View

16.

Johnstone R, Ruefli A, Lowe S . Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108(2):153-64. DOI: 10.1016/s0092-8674(02)00625-6. View

17.

Ma X, Ezzeldin H, Diasio R . Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009; 69(14):1911-34. DOI: 10.2165/11315680-000000000-00000. View

18.

Marchion D, Munster P . Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 2007; 7(4):583-98. DOI: 10.1586/14737140.7.4.583. View

19.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay H . Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol. 2007; 212(2):330-44. DOI: 10.1002/jcp.21066. View

20.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View